Kevin P Baker

Summary

Affiliation: Human Genome Sciences
Country: USA

Publications

  1. ncbi request reprint Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
    Kevin P Baker
    Human Genome Sciences, Inc, Rockville, Maryland 20850, USA
    Arthritis Rheum 48:3253-65. 2003
  2. ncbi request reprint BLyS--an essential survival factor for B cells: basic biology, links to pathology and therapeutic target
    Kevin P Baker
    Department of Antibody Discovery and Development, Human Genome Sciences Inc, 14200 Shady Grove Road, Rockville, MD 20850, USA
    Autoimmun Rev 3:368-75. 2004
  3. ncbi request reprint Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects
    Wendy G Halpern
    Human Genome Sciences, Inc, Rockville, Maryland 20850, USA
    Toxicol Sci 91:586-99. 2006
  4. ncbi request reprint BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases
    Viktor Roschke
    Department of Antibody Development, Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850, USA
    J Immunol 169:4314-21. 2002
  5. ncbi request reprint B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations
    William Stohl
    Los Angeles County University of Southern California Medical Center, and University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Arthritis Rheum 48:3475-86. 2003

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
    Kevin P Baker
    Human Genome Sciences, Inc, Rockville, Maryland 20850, USA
    Arthritis Rheum 48:3253-65. 2003
    ..Elevated levels of BLyS have been implicated in the pathogenesis of autoimmune diseases...
  2. ncbi request reprint BLyS--an essential survival factor for B cells: basic biology, links to pathology and therapeutic target
    Kevin P Baker
    Department of Antibody Discovery and Development, Human Genome Sciences Inc, 14200 Shady Grove Road, Rockville, MD 20850, USA
    Autoimmun Rev 3:368-75. 2004
    ..Multiple approaches are being taken to antagonize BLyS including a fully human antibody and soluble BLyS receptors. These approaches are currently being tested in clinical trials...
  3. ncbi request reprint Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects
    Wendy G Halpern
    Human Genome Sciences, Inc, Rockville, Maryland 20850, USA
    Toxicol Sci 91:586-99. 2006
    ..The favorable safety profile and lack of treatment-related infections also support continued clinical development of belimumab...
  4. ncbi request reprint BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases
    Viktor Roschke
    Department of Antibody Development, Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850, USA
    J Immunol 169:4314-21. 2002
    ..These findings raise the possibility that active BLyS/APRIL heterotrimers may play a role in rheumatic and other autoimmune diseases and that other members of the TNF ligand superfamily may also form active soluble heterotrimers...
  5. ncbi request reprint B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations
    William Stohl
    Los Angeles County University of Southern California Medical Center, and University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Arthritis Rheum 48:3475-86. 2003
    ..To assess the overexpression of B lymphocyte stimulator (BLyS) over time in patients with systemic lupus erythematosus (SLE)...